Preview

Пульмонология

Расширенный поиск

Стратегия длительной комбинированной терапии бронхиальной астмы: клинико-патогенетическое обоснование

https://doi.org/10.18093/0869-0189-2006-2-121-126

Полный текст:

Об авторе

Б.А. Черняк

Россия


Список литературы

1. Глобальная стратегия лечения и профилактики бронхиальной астмы (GINA). Пересмотр 2002 г.: Пер. с агнл М.: Атмосфера; 2002.

2. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58 (suppl. I): i1-i94.

3. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma control study. Am. J. Respir. Crit. Care Med. 2004; 170: 836-844.

4. FitzGerald J.M., Sears M.R., Boulet L.P. et al. Adjustable maintenance dosing with budesonide / formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can. Respir. J. 2003; 10 (8): 427-434.

5. Leuppi J.D., Salzberg M., Meyer L. et al. An individualized, adjustable maintenance regimen of budesonide / formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss. Med. Wkly 2003; 133: 302-329.

6. Aalbers R., Backer V., Kava T.T. et al. Adjustable maintenance dosing with budesonide / formoterol compared with fixed-dose salmeterol / fluticasone in moderate to severe asthma. Curr. Med. Res. Opin. 2004; 20 (2): 225-240.

7. FitzGerald J.M., Boulet L.P., Follows RMA. The CONCEPT Trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol / fluticasone propionate with an adjustable maintenance dosing regimen of formoterol / budesonide in adults with persistent asthma. Clin. Ther. 2005; 27 (4): 393-406.

8. Reddel H.K., Jenkins C.R., Marks G.B. et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur. Respir. J. 2000; 21 (1): 226-235.

9. Woolcock A.J. What are the important questions in the treatment of asthma? Clin. Exp. Allergy Rev. 2001; 1 (2): 62-64.

10. Pedersen S. Presented at ERS, Copenhagen, September 18, 2005.

11. de Kluijver J., Evertse C.E., Schrumpf J.A. et al. Asymptomatic worsening of airway inflammation during low dose allergen exposure in asthma: Protection by inhaled steroids. Am. J. Respir. Crit. Care Med. 2002; 166: 294-300.

12. Ward C., Pais M., Bish R. et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57 (4): 309-316.

13. Green R.H., Brightling C.E., McKenna S. et al. Asthma exacerbations and sputum eosinophil counts: A randomized controlled trial. Lancet 2002; 360: 1715-1721.

14. Sont J.K., Willems L.N., Bel E.H. et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am. J. Respir. Crit. Care Med. 1999; 159: 1043-1051.

15. FitzGerald J.M., Becker A., Sears M. et al. Doubling the dose of budesonide ver sus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-556.

16. Harrison T.W., Oborne J., Newton S., Tattersfield A.E. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: Randomised controlled trial. Lancet 2004; 363: 271-275.


Для цитирования:


Черняк Б. Стратегия длительной комбинированной терапии бронхиальной астмы: клинико-патогенетическое обоснование . Пульмонология. 2006;(2):121-126. https://doi.org/10.18093/0869-0189-2006-2-121-126

Просмотров: 34


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)